Shots:

• The US FDA has granted FTD for NGM621 to treat patients with GA secondary to AMD. NGM621 (q4w or q8w, IVT inj.) is currently being evaluated in an ongoing P-II (CATALINA) study in a ratio (2:1:2:1) in 320 patients & the results are expected in Q4’22
• The primary efficacy EPs of the P-II (CATALINA) study is the rate of change in the GA lesion area as measured by FAF imaging @52wks. while the primary safety EPs will assess the incidence & severity of ocular & systemic AEs from treatment with NGM621 over sham control
• In the P-I study, the therapy showed single & multiple IVT inj. were reported to be safe and well-tolerated. NGM621 is a mAb product candidate engineered to potently inhibit complement C3

Ref: Globe Newswire | Image: NGM Bio